Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Fig. 4

Effects of DA (5 µM) and BMS-202 (5 µM) on cell invasion of human HER2-positive breast cancer cell lines, SKBR3 and ZR75 for 48 h. DA and BMS-202 inhibit the cell invasion ability of (a) SKBR3 and (b) ZR75 cell lines using Matrigel® Invasion Chambers. We note that cancer cells treated for 48 h with DA and BMS-202 show significant inhibition of cell invasion in both cell lines compared with their matched control. Data are quantified by normalizing the number of invasive cells by their total number. Data are expressed as the number of invasive cells per field ± SEM

Back to article page